LAS VEGAS, NV--(Marketwired - Jan 25, 2016) - Cell MedX Corp. (
The observational reports can be found at www.cellmedx.com/observations and will be updated frequently. New users are being actively solicited to participate in the ongoing research and the Company expects the data will prove extremely useful to its development aims.
The eBalance Pro device is designed to study targeted effects on glucose control, increased insulin sensitivity and insulin resistance, abatement of diabetic neuropathy, accelerated wound healing as well as pain management for both non-diabetic and diabetic patients.
Cell MedX President and CEO Mr. Frank McEnulty states, "Our early results propelled us to commence the manufacture of additional units and to get them in use as quickly as possible. We are receiving excellent user responses to the device and its documented efficacy is on track and improvements will be duly noted as we increase our user base. As noted previously, we anticipate that practical use of the units will translate into the potential for increased interest and future demand as we move forward towards commercialization. We thank everyone for their interest and are delighted to be moving ahead."
About Cell MedX Corp. (
Cell MedX Corp. is a development stage company focused on the commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. For more information go to: www.cellmedx.com and visit us on Facebook.
On behalf of the Board of Directors of Cell MedX Corp.
Chief Executive Officer and President.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects," "aims," "intends," "estimates," "projects," "anticipates," "believes," "could," "possibility" and other similar words. All statements addressing product performance, observations, studies, results, revenues, demand, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company's forward-looking statements. In particular, the Company's e-balance Technology is still in development. The Company does not currently have any commercially marketable products based on the e-balance technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.